Contact : Anne Bancillon 33-6-86-31-03-89 ~ Taxotere®-Based Chemotherapy Reduces Risk of Death by 23 Percent ~ Final results from the largest international study in the reatment of advanced stomach cancer, also known as gastric cancer, demonstrated that patients who received a Taxotere® (docetaxel) Injection Concentrate-based chemotherapy regimen (Taxotere®, cisplatin and 5-fluorouracil)
market growth1 at 11.9%2 on a comparable basis Strong growth in adjusted EPS3: up 27.7%2 at 1.06 euros per share Sanofi-aventis on track to meet 2005 guidance The consolidated statement of income of sanofi-aventis for the first quarter of 2005, presented in Appendix 4, shows net income of 531 million euros and is impacted by the accounting treatment of the combination with Aventis and by re
Press release from Professor Luc Van Gaal (University Hospital Antwerp), principal investigator of the Rio-Europe trial, entitled: 1st year results of RIO-EUROPE study published in the Lancet. Best regards, Media Relations Department 174, avenue de France - 75013 PARIS - FRANCE - Tél. : +33 1.53.77.40.00 - Fax : +33 1.53.77.41.33 - www.sanofi-aventis.com Sanofi-aventis - Siège Social :
Contact : Dr. Robert SEBBAG +33 (0)1 53 77 47 80 +33 (0)6 08 17 21 83 EMBARGO UNTIL APRIL 15, 2005 1:00 p.m. (CET) In his address to the closing plenary session of BioVision the World Life Sciences Forum - Jean-François Dehecq, Chairman and CEO of sanofi-aventis, set out the guiding principles of his Group's strategy in its Policy of Access to Medicines in the "Southern Countries".
FDA ISSUES APPROVABLE LETTER FOR AMBIEN CR (ZOLPIDEM TARTRATE EXTENDED RELEASE) CIV FOR THE TREATMENT OF INSOMNIA Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for AMBIEN CR (zolpidem tartrate extended release) CIV. AMBIEN CR is the controlled-release formulation of zolpidem, the worlds
Major U.S. public health initiative complements sanofi pasteurs leadership in global pandemic preparedness Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has been awarded a $97 million contract from the U.S. Health and Human Services Department (HHS) to speed the production process for new cell culture influenza vaccines in the U.S. and the design of a U.S.-based cell-cultu
Sanofi-aventis announced today the simultaneous signature of a medium-term syndicated credit agreement amounting to 8 billion and four bilateral credit facilities amounting to 500 million each. The syndicated credit agreement consists of two revolving credit lines each having a different maturity: a 5.5 billion five-year tranche with the possibility of extending the maturity up to seven
Today sanofi-aventis announced that, at the request of sanofi-aventis, Apotex, and their respective affiliates, the U.S. District Court for the Southern District of New York has approved an extension of the date for submission by the parties of the pre-trial order in its Plavix® patent-infringement litigation with Apotex and Dr. Reddys Laboratories. The new date is May 13, 2005. The submission
in partnership with the Nelson Mandela Foundation and the South African Department of Health THE TB FREE PROGRAM for the treatment of tuberculosis sufferers In Johannesburg today, South African Health Minister Dr. Manto Tshabalala-Msimang and sanofi-aventis Chairman and CEO Jean-François Dehecq inaugurated the first training center in support for patients receiving treatment for tuberculosi
The Canadian Federal Court of Ottawa has granted sanofi-aventiss application for an order of prohibition against the Minister of Health and Apotex Inc. in relation to Apotexs 2003 application in Canada for a marketing authorization for a generic version of clopidogrel bisulfate tablets. The Canadian Court rejected Apotex's challenge to the Plavix® patent and held that the asserted claims are nov
Vaccine Leader Looks to Introduce First Pertussis Booster for Both Adolescents and Adults in United States Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) voted unanimously to recommend licensure of ADACEL (Tetanus Toxoi
Submits supplemental license application Sanofi Pasteur, the vaccines business of the sanofi-aventis Group, is seeking U.S. government approval to broaden the age indication for its new meningococcal vaccine Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine). The company has filed a supplemental application with the U.S. Food and Drug Adminis
Sanofi-aventis has learned through the Canadian Ministry of Health website that Novopharm Limited had obtained marketing approval in Canada for a product claiming to be generic enoxaparin. Sanofi-aventis companies Aventis Pharma Inc. and Aventis Pharma S.A. are bringing suit in the Federal Court against Novopharm for patent infringement of Canadian patent 2045433, which covers Lovenox®. Sanofi
Results from two major clinical trials presented at ACC (PARIS and PRINCETON, NJ, MARCH 9, 2005) Results of two major clinical trials showed that the antiplatelet agent clopidogrel, given on top of standard therapy, provided significant benefits to patients with acute ST-segment elevation myocardial infarction (STEMI), a certain kind of heart attack. Results of the COMMIT/CCS-2 (ClOpidogrel
Pfizer Inc. and the sanofi-aventis Group announced today that the United States Food and Drug Administration (FDA) has accepted for filing a new drug application for Exubera® (inhaled human insulin powder). Exubera®, a dry powder form of insulin that is inhaled into the lungs prior to eating, using a specially designed inhalation device, has been studied in more than 3,500 patients, some for o
Tommy Olin, commercial operations director, med ansvar för sanofi-aventis sälj- och marknadsorganisation har valt att lämna företaget för att gå vidare i en ny karriär utanför organisationen. Han lämnar sanofi-aventis vid månadsskiftet. För ytterligare information kontakta Annette Hedman, tf informationsanvarig, 08-470 18 52 eller 070-289 88 64. Koncernen sanofi-aventis är det tredje störst
Sanofi-aventis announced today that he has received marketing approval from the United States Food and Drug Administration for a new formulation of Eloxatin® (oxaliplatin for injection). This new formulation, Eloxatin® INJECTION, is a clear, preservative-free, colorless solution which does not require reconstitution. Eloxatin® INJECTION offers additional benefit and convenience to physicians an
TWO STUDIES DEMONSTRATE SIGNIFICANT BENEFIT OF ELOXATIN BASED CHEMOTHERAPY COMBINED WITH BEVACIZUMAB IN ADVANCED COLORECTAL CANCER Positive Results of TREE-2 and ECOG 3200 Trials Presented at the 2005 Gastrointestinal Cancers Symposium in Hollywood, Florida Sanofi-aventis (NYSE: SNY) announced today preliminary results of two large prospective trials evaluating the safety and efficacy of E
Sanofi-aventis gains market share from year one After consultation with the stock market authorities in France and the United States, sanofi-aventis has retained August 20 as the date of first consolidation. In 2004, sanofi-aventis generated consolidated net sales of 15,043 million euros compared with 8,048 million euros in 2003. In the fourth quarter of 2004, sanofi-aventis consolidated net
EU-kommissionen har godkänt sanofi-aventis läkemedel Taxotere (docetaxel) för adjuvant behandling, det vill säga direkt efter operation, vid tidig körtelpositiv bröstcancer. Kommissionens beslut baseras på resultatet av en stor långtidsstudie som visar på både en ökad överlevnad och minskad risk för återfall vid behandling med Taxotere. - Detta är framsteg vad gäller bröstcancerbehandling. Resu